MedTrace Logo

A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV

NCT05005078 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-12-04

No results posted yet for this study

Summary

This is a two-part study of the safety, tolerability, and efficacy of topically administered WST-057 for 16 weeks in subjects with HIV with sensory polyneuropathy.

Conditions

  • HIV Associated Polyneuropathy

Interventions

DRUG

WST-057

WST-057 topical solution

DRUG

Placebo

WST-057 Matching placebo

Sponsors & Collaborators

  • WinSanTor, Inc

    lead INDUSTRY

Principal Investigators

  • Angela Hansen · WinSanTor, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-24
Primary Completion
2023-01-18
Completion
2023-01-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05005078 on ClinicalTrials.gov